ZNRD2抗体—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hela, 231 and A549 cell, Mouse liver tissue lysates, Primary antibody: P03036(ZNRD2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P03036(ZNRD2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P03036(ZNRD2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

ZNRD2 (Zinc Ribbon Domain-Containing Protein 2), also known as DNA-directed RNA polymerase I subunit RPA12. is a protein encoded by the ZNRD2 gene in humans. It is a conserved component of RNA polymerase I (Pol I), playing a critical role in ribosomal RNA (rRNA) transcription within the nucleolus. ZNRD2 contains a zinc ribbon domain, a structural motif involved in nucleic acid binding and protein-protein interactions. Its function is essential for cell viability, as rRNA synthesis is fundamental to ribosome biogenesis and cellular proliferation.

Antibodies targeting ZNRD2 are primarily used in research to study its expression, localization, and role in Pol I-mediated transcription. These antibodies enable the detection of ZNRD2 via techniques such as Western blotting, immunofluorescence, and immunoprecipitation. Due to ZNRD2's involvement in ribosome synthesis, dysregulation of its expression or activity has been linked to diseases characterized by uncontrolled cell growth, including certain cancers. Researchers utilize ZNRD2 antibodies to explore its potential as a biomarker or therapeutic target in oncology.

Most commercially available ZNRD2 antibodies are raised in rabbits or mice, with specificity validated using knockout cell lines or siRNA-mediated knockdown. Applications often focus on understanding ZNRD2's interaction with other Pol I subunits and its response to cellular stressors or chemotherapeutic agents. Proper controls, such as isotype-matched antibodies and target peptide competition, are recommended to ensure assay specificity.